A 48-year-old woman with a gastric ulcer refractory to 8 weeks of omeprazole therapy is found to be H. pylori-negative on repeat endoscopy with biopsy. NSAIDs were discontinued 2 months ago. What is the drug of choice for long-term management of this refractory ulcer?

Explanation

## Refractory Peptic Ulcer Disease: PPI Dose Escalation **Key Point:** Refractory ulcers (those failing to heal after 8–12 weeks of standard-dose PPI therapy) require **dose escalation of the PPI**, typically to 40 mg once daily or higher, especially in H. pylori-negative, NSAID-negative cases. ### Definition and Epidemiology **High-Yield:** A refractory ulcer is defined as: - Failure to heal after ≥8 weeks of standard-dose PPI therapy (e.g., omeprazole 20 mg daily) - Absence of H. pylori infection (confirmed by repeat endoscopy with biopsy) - No ongoing NSAID use Refractory ulcers occur in 5–10% of peptic ulcer patients and often indicate: - Inadequate acid suppression - Zollinger-Ellison syndrome (rare) - Malignancy (must exclude) - Poor compliance ### Management Algorithm ```mermaid flowchart TD A[Peptic ulcer on standard-dose PPI for 8 weeks]:::outcome --> B{Healed?}:::decision B -->|Yes| C[Continue PPI maintenance]:::action B -->|No| D[Refractory ulcer]:::outcome D --> E{H. pylori status?}:::decision E -->|Positive| F[Triple therapy + PPI]:::action E -->|Negative| G{NSAID use?}:::decision G -->|Yes| H[Discontinue NSAID + increase PPI dose]:::action G -->|No| I[Escalate PPI to 40 mg daily or higher]:::action I --> J[Consider ZES workup if refractory]:::action ``` ### PPI Dose Escalation Strategy | Scenario | Standard Dose | Escalated Dose | Rationale | |----------|---------------|----------------|----------| | H. pylori-negative, NSAID-negative refractory ulcer | Omeprazole 20 mg daily | Omeprazole 40 mg daily (or 20 mg BD) | Increases gastric pH to >4 for >18 hrs/day; promotes ulcer healing | | Zollinger-Ellison syndrome (suspected) | — | Omeprazole 60–80 mg daily (divided doses) | Requires profound acid suppression | | Severe refractory ulcer | — | Pantoprazole 40 mg BD or higher | Alternative PPI if inadequate response | **Clinical Pearl:** Doubling the PPI dose (from 20 mg to 40 mg daily) increases the duration of gastric pH >4 from ~8 hours to ~16–18 hours, which significantly accelerates ulcer healing. ### Why Higher-Dose PPI? 1. **Pharmacokinetics:** PPIs have a short half-life (~1 hour); once-daily dosing may be insufficient for continuous acid suppression in some patients. 2. **Genetic variation:** CYP2C19 polymorphisms affect PPI metabolism; some patients are "slow metabolizers" and require higher doses. 3. **Healing rate:** Higher-dose PPI therapy achieves ulcer healing in >90% of refractory cases within 4–8 additional weeks. **Mnemonic:** **REFRACTORY = Raise Escalate For Refractory Acid Control To Optimize Resistant Yulcers** (Escalate PPI dose) ### Exclusions Before Dose Escalation **Warning:** Before escalating PPI, always exclude: - **Malignancy:** Gastric ulcers can be malignant; confirm benign histology on endoscopy. - **Zollinger-Ellison syndrome:** Fasting serum gastrin >1000 pg/mL or gastrin-stimulation test if gastrin 100–1000 pg/mL. - **Continued NSAID use:** Patient must confirm discontinuation; some may be taking over-the-counter NSAIDs unknowingly. [cite:Harrison 21e Ch 297]